|
See related Cordarone information |
|
|
|
Manufacturer |
sanofi-aventis |
|
Distributor |
DKSH |
|
Contents |
Amiodarone HCl |
|
Indications |
Tab Prevention of recurrences of ventricular tachycardia, arrhythmia & fibrillation; supraventricular tachycardia. Treatment of supraventricular tachycardia in the presence of coronary artery disease &/or impaired left ventricular function. Amp Atrial arrhythmias, Wolf-Parkinson-White syndrome tachycardia, ventricular arrhythmia, cardiopulmonary resuscitation.
Click to view Cordarone detailed prescribing infomation |
|
Dosage |
Tab 1 tab tid for 8-10 days. Maintenance: ½ tab every 2 days to 2 tab daily. Amp IV infusion: Initially 5 mg/kg over 20 min-2 hr. Maintenance: 10-20 mg/kg/day over a few days. Direct IV inj: Cardiopulmonary resuscitation Initially 300 mg (5 mg/kg). May have additional 150 mg (2.5 mg/kg) if needed.
Click to view Cordarone detailed prescribing infomation |
|
Overdosage |
View Cordarone overdosage for action to be taken in the event of an overdose. |
|
Administration |
May be taken with or without food (Administer consistently w/ regard to meals. Take w/ meals if high dose or to reduce GI discomfort.). |
|
Contraindications |
Sinus bradycardia, SA heart block & sinus node disease w/o prosthesis, AV conduction disorders, circulatory collapse, severe hypotension, hyperthyroidism, iodine hypersensitivity, combination w/ drugs that induce torsades de pointes. Pregnancy, lactation.
Click to view Cordarone detailed prescribing infomation |
|
Special Precautions |
Electrolyte disturbances. Avoid sun exposure.
Click to view Cordarone detailed prescribing infomation |
|
Adverse Drug Reactions |
Reversible corneal microdeposits; hyper- or hypothyroidism; photosensitization, pigmentation, diffuse interstitial pneumopathy or peripheral neuropathy.
View ADR Monitoring Form |
|
Drug Interactions |
Antiarrhythmics, β-blockers, stimulating laxatives, diuretics inducing hypokalemia, systemic corticosteroids, tetracosactide, amphotericin B, digitalis, anticoagulants, phenytoin, general anesth, cyclosporin.
View more drug interactions with Cordarone |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
Caution For Usage |
For caution against possible variation of physical aspect of medicine... click to view Cordarone detailed prescribing infomation |
|
Description |
View Cordarone description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Cordarone mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Cordarone tablet |
|
Cordarone 200 mg x 30's |
 |
|
|
Cordarone injection |
|
Cordarone 150 mg/3 mL x 6's |
|
|
|
Manufacturer: |
sanofi-aventis |
|
Distributor: |
DKSH
|
|
|
|
